Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 13/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144633 | 0.88 | CASR (0.71) | CASRHDAC1HDAC8HDAC6NR1I2 | |
| SCHEMBL4138763 | 0.88 | CASR (0.63) | CASRHDAC1HDAC8HDAC6NR1I2 | |
| SCHEMBL14535968 | 0.86 | CASR (0.69) | CASRHDAC1HDAC8HDAC6NR1I2 | |
| SCHEMBL4140148 | 0.84 | CASR (0.49) | CASRHDAC1HDAC8HDAC6 | |
| SCHEMBL4139279 | 0.83 | CASR (0.64) | CASRHDAC1HDAC8HDAC6NR1I2 | |
| SCHEMBL5098015 | 0.82 | CASR (0.57) | CASRHDAC1HDAC8HDAC6NR1I2 | |
| SCHEMBL5746615 | 0.81 | CASR (1.00) | CASRGFER | |
| SCHEMBL4151289 | 0.80 | CASR (0.82) | CASRNR1I2 | |
| SCHEMBL4143340 | 0.78 | CASR (0.76) | CASRNR1I2 | |
| SCHEMBL4161402 | 0.78 | CASR (0.67) | CASRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | claimed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| CN-101360498-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2009-02-04 | — | — | CN | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | CASR 12/4885HDAC1 4096/4885HDAC8 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.